Related Party Transactions	3 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	12. RELATED PARTY TRANSACTIONS Oxford Biomedica Solutions LLC As described in Note 5, the Company has significant influence over, but does not control, OXB Solutions through its noncontrolling representation on OXB Solution’s board of directors and the Company’s equity interest in OXB Solutions. In March 2022, concurrently with the closing of the transaction with OXB Solutions, the Company entered into certain ancillary agreements with OXB Solutions including a supply agreement, a lease assignment and assumption agreement, a sublease agreement and a transitional services agreement. Supply Agreement Pursuant to the terms of the Manufacturing and Supply Agreement with OXB Solutions entered into in March 2022 (the "Supply Agreement"), the Company has agreed to purchase from OXB Solutions at least 50% of its clinical supply requirements of AAV-based products during the initial term of the supply agreement. The Supply Agreement provides for an initial term of three years, which may be extended for an additional one-year term. Under the Supply Agreement, the Company is committed to purchase a minimum number of batches of drug substance and drug product, as well as process development services, totaling approximately $29.7 million in 2023. There are no minimum purchase commitments in 2024 (year three) of the Supply Agreement. After the initial term, the Company will have the right to terminate the Supply Agreement for convenience or other reasons specified in the Supply Agreement upon prior written notice. Either party may terminate the Supply Agreement upon an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. During the three months ended March 31, 2023, the Company recorded purchases of drug substance from OXB Solutions related to the Supply Agreement of $4.9 million, as well as purchases of process development services of approximately $1.2 million and stability services and other support of approximately $0.5 million. During the three months ended March 31, 2022, the Company recorded purchases of process development services from OXB Solutions related to the Supply Agreement of approximately $1.1 million. These amounts are included within research and development expenses on the Company's condensed consolidated statements of operations. The amounts due to OXB Solutions under the Supply Agreement were $4.9 million and $5.2 million as of March 31, 2023 and December 31, 2022, respectively, and were included in accrued expenses and other liabilities on the Company's condensed consolidated balance sheets. Lease Assignment and Sublease Agreement As described in Note 8, the Company leases space for research and development, manufacturing and general office space in Bedford, Massachusetts. The Company and OXB Solutions entered into a lease assignment and assumption agreement pursuant to which Homology assigned all of its right, title and interest in, to and under this lease to OXB Solutions and a sublease agreement whereby OXB Solutions subleased certain premises in its facility to Homology. However, as the Company remains jointly and severally liable for the payment of rent under this lease, the Company has not been released from being the primary obligor under such lease and therefore the related right-of-use asset and operating lease liability were not derecognized and remain on the Company’s condensed consolidated balance sheets. Therefore, the Company is recording sublease income from OXB Solutions as if it were subleasing the space to OXB Solutions. During the three months ended March 31, 2023 and 2022, the Company recorded sublease income of $0.8 million and $0.3 million, respectively, related to the sublease agreement with OXB Solutions. This amount was recognized as a reduction to lease expense in the Company's condensed consolidated statements of operations. As of March 31, 2023 and December 31, 2022, the amount of sublease income receivable from OXB Solutions was $0.3 million and $0.5 million, respectively, and was included in prepaid expenses and other current assets on the Company's condensed consolidated balance sheets. Transitional Services Agreement Under the transitional services agreement with OXB Solutions (the “Services Agreement”), the Company is performing certain services for the benefit of OXB Solutions and OXB Solutions is performing certain services for the benefit of the Company. The term of the Services Agreement will not exceed eighteen months and lasts until the earlier of termination for convenience, termination for cause in the event of an uncured material breach, termination as a result of bankruptcy of either party, and expiration or termination of the only remaining outstanding service as set forth in the Services Agreement. Each company is fully reimbursing the other for these services. Expenses incurred by the Company for services provided by OXB Solutions recognized under the Services Agreement totaled $0.2 million and less than $0.1 million for the three months ended March 31, 2023 and 2022, respectively, and are presented within research and development expenses in the condensed consolidated statements of operations as the services related to facilities support within the Company's research and development labs. As of March 31, 2023 and December 31, 2022, the amount due to OXB Solutions under the Services Agreement was $0.1 million, and was included in accrued expenses and other liabilities on the Company's condensed consolidated balance sheets. The Company provided finance, human resources, IT and legal services to OXB Solutions under the Services Agreement and recognized $0.3 million and $0.6 million for the three months ended March 31, 2023 and 2022, respectively, for amounts reimbursed by OXB Solutions as a reduction to general and administrative expense in the Company's condensed consolidated statements of operations. As of March 31, 2023 and December 31, 2022, the Company had a receivable balance of $0.1 million and $0.3 million, respectively, from OXB Solutions which was recorded as a component of prepaid expenses and other current assets in the Company's condensed consolidated balance sheets. Pursuant to the Services Agreement, the Company has been paying vendors on OXB Solutions' behalf; this process will be fully transitioned to OXB Solutions this year. As of March 31, 2023 and December 31, 2022, the amount receivable from OXB Solutions for amounts paid to vendors on their behalf was $0.6 million and $1.1 million, respectively, and was included in prepaid expenses and other current assets on the Company's condensed consolidated balance sheets.

Related Party Transactions

3 Months Ended

Mar. 31, 2023

12. RELATED PARTY TRANSACTIONS

Oxford Biomedica Solutions LLC

As described in Note 5, the Company has significant influence over, but does not control, OXB Solutions through its noncontrolling representation on OXB Solution’s board of directors and the Company’s equity interest in OXB Solutions. In March 2022, concurrently with the closing of the transaction with OXB Solutions, the Company entered into certain ancillary agreements with OXB Solutions including a supply agreement, a lease assignment and assumption agreement, a sublease agreement and a transitional services agreement.

Supply Agreement

Pursuant to the terms of the Manufacturing and Supply Agreement with OXB Solutions entered into in March 2022 (the "Supply Agreement"), the Company has agreed to purchase from OXB Solutions at least 50% of its clinical supply requirements of AAV-based products during the initial term of the supply agreement. The Supply Agreement provides for an initial term of three years, which may be extended for an additional one-year term. Under the Supply Agreement, the Company is committed to purchase a minimum number of batches of drug substance and drug product, as well as process development services, totaling approximately $29.7 million in 2023. There are no minimum purchase commitments in 2024 (year three) of the Supply Agreement. After the initial term, the Company will have the right to terminate the Supply Agreement for convenience or other reasons specified in the Supply Agreement upon prior written notice. Either party may terminate the Supply Agreement upon an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party.

During the three months ended March 31, 2023, the Company recorded purchases of drug substance from OXB Solutions related to the Supply Agreement of $4.9 million, as well as purchases of process development services of approximately $1.2 million and stability services and other support of approximately $0.5 million. During the three months ended March 31, 2022, the Company recorded purchases of process development services from OXB Solutions related to the Supply Agreement of approximately $1.1 million. These amounts are included within research and development expenses on the Company's condensed consolidated statements of operations. The amounts due to OXB Solutions under the Supply Agreement were $4.9 million and $5.2 million as of March 31, 2023 and December 31, 2022, respectively, and were included in accrued expenses and other liabilities on the Company's condensed consolidated balance sheets.

Lease Assignment and Sublease Agreement

As described in Note 8, the Company leases space for research and development, manufacturing and general office space in Bedford, Massachusetts. The Company and OXB Solutions entered into a lease assignment and assumption agreement pursuant to which Homology assigned all of its right, title and interest in, to and under this lease to OXB Solutions and a sublease agreement whereby OXB Solutions subleased certain premises in its facility to Homology. However, as the Company remains jointly and severally liable for the payment of rent under this lease, the Company has not been released from being the primary obligor under such lease and therefore the related right-of-use asset and operating lease liability were not derecognized and remain on the Company’s condensed consolidated balance sheets. Therefore, the Company is recording sublease income from OXB Solutions as if it were subleasing the space to OXB Solutions.

During the three months ended March 31, 2023 and 2022, the Company recorded sublease income of $0.8 million and $0.3 million, respectively, related to the sublease agreement with OXB Solutions. This amount was recognized as a reduction to lease expense in the Company's condensed consolidated statements of operations. As of March 31, 2023 and December 31, 2022, the amount of sublease income receivable from OXB Solutions was $0.3 million and $0.5 million, respectively, and was included in prepaid expenses and other current assets on the Company's condensed consolidated balance sheets.

Transitional Services Agreement

Under the transitional services agreement with OXB Solutions (the “Services Agreement”), the Company is performing certain services for the benefit of OXB Solutions and OXB Solutions is performing certain services for the benefit of the Company. The term of the Services Agreement will not exceed eighteen months and lasts until the earlier of termination for convenience, termination for cause in the event of an uncured material breach, termination as a result of bankruptcy of either party, and expiration or termination of the only remaining outstanding service as set forth in the Services Agreement. Each company is fully reimbursing the other for these services.

Expenses incurred by the Company for services provided by OXB Solutions recognized under the Services Agreement totaled $0.2 million and less than $0.1 million for the three months ended March 31, 2023 and 2022, respectively, and are presented within research and development expenses in the condensed consolidated statements of operations as the services related to facilities support within the Company's research and development labs. As of March 31, 2023 and December 31, 2022, the amount due to OXB Solutions under the Services Agreement was $0.1 million, and was included in accrued expenses and other liabilities on the Company's condensed consolidated balance sheets.

The Company provided finance, human resources, IT and legal services to OXB Solutions under the Services Agreement and recognized $0.3 million and $0.6 million for the three months ended March 31, 2023 and 2022, respectively, for amounts reimbursed by OXB Solutions as a reduction to general and administrative expense in the Company's condensed consolidated statements of operations. As of March 31, 2023 and December 31, 2022, the Company had a receivable balance of $0.1 million and $0.3 million, respectively, from OXB Solutions which was recorded as a component of prepaid expenses and other current assets in the Company's condensed consolidated balance sheets. Pursuant to the Services Agreement, the Company has been paying vendors on OXB Solutions' behalf; this process will be fully transitioned to OXB Solutions this year. As of March 31, 2023 and December 31, 2022, the amount receivable from OXB Solutions for amounts paid to vendors on their behalf was $0.6 million and $1.1 million, respectively, and was included in prepaid expenses and other current assets on the Company's condensed consolidated balance sheets.